CD163 and neoplasm: Notably, Siglec-1/CD163 is associated with the activation of macrophages towards an immunosuppressive phenotype, and accordingly, the expression of both CAF (FAP) and TAM (SIGLEC1) markers is associated with poor clinical outcomes across multiple tumor types53–56.